Case Report

Thymic hyperplasia due to excess growth hormone stimulation: A case report

Claire Brookmeyer, MD*, Elliot K. Fishman, MD

Russell H. Morgan Department of Radiology, Johns Hopkins School of Medicine, 601 N Caroline St, Baltimore, MD, USA

Article history:
Received 11 January 2022
Accepted 15 January 2022

Abstract

Growth hormone has a strong role in stimulation of the thymus. We report a case of thymic hyperplasia due to excess endogenous growth hormone in the setting of acromegaly. Acromegaly often presents with systemic manifestations that may be confused with a systemic hematologic malignancy or infection, especially if an anterior mediastinal mass is present but unrecognized as a benign thymic hyperplasia. It is important for radiologists to be aware of this association between growth hormone and thymic stimulation because it may increase confidence diagnosing thymic hyperplasia in this setting, and avoid unnecessary mediastinal biopsy or surgery.

© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

The thymus is a target organ for growth hormone (GH), although it's effects may be underappreciated by radiologists because they are rarely visualized on imaging. Thymic hyperplasia may be induced by endogenous growth hormone excess, such as acromegaly, or exogenous growth hormone administered in cases of immunodeficiency or growth hormone deficiency. Here we report a case of thymic hyperplasia in a patient presenting with a complex constellation of symptoms mimicking malignancy and infection, but ultimately found to be due to a GH-secreting pituitary macroadenoma. To our knowledge, this is the second reported case of thymic hyperplasia due to acromegaly.

Case Report

A 37-year-old previously healthy male was in his usual state of health when he developed a complex constellation of symptoms with sore neck, hoarse voice, coughing, arthralgias, weight loss, swollen neck glands, fatigue, headache, night sweats, enlargement of his right testicle, and trouble with comprehension and memory.

*Disclosures/Competing Interests: C. Brookmeyer: No disclosures. E.K. Fishman: General Electric educational grant support (Hopkins), Siemens research grant support (Hopkins), HipGraphics Inc- co-founder and shareholder.
*Corresponding author.
E-mail address: cbrookm2@jhmi.edu (C. Brookmeyer).
Infectious disease testing including Covid-19, HIV, mononucleosis, and Lymes disease were all negative. CT of the chest, abdomen and pelvis revealed an anterior mediastinal mass, which was initially read as suspicious for lymphoma or thymic mass at an outside hospital (Fig. 1A). Cervical lymph node biopsy was negative for malignancy. MR of the brain was obtained due to the headaches and difficulties with mentation, and showed a large 2 cm pituitary mass with suprasellar extension (Fig. 2). Laboratory evaluation showed markedly elevated IGF-1 of 623 ng/ml (normal <331 ng/mL), and elevated Growth Hormone of 17.7 ng/mL (normal <7.1 ng/mL). Prolactin was also elevated at 85.2 ng/mL (normal <18.0 ng/mL). These findings were consistent with acromegaly due to a growth-home secreting pituitary macroadenoma.

The patient underwent transphenoidal resection of the pituitary macroadenoma nine months after initial presentation. Pathology of the surgical specimen showed a mammomatosatroph pituitary adenoma. Following surgical resection of the pituitary adenoma, his Growth Hormone dropped to a nadir of 0.7 ng/mL.

Follow-up CT of the chest obtained 4 months following resection of the pituitary macroadenoma showed an anterior mediastinal mass with triangular shape and smooth contours (Fig. 1B). The mass had decreased in size since initial imaging; volumetric segmentation performed on the CT showed that the mass had decreased in volume from 53 cc to 35 cc. Cinematic rendering of the mass from the CT data set provided a photorealistic evaluation of the mass, nicely demonstrating the internal architecture with interspersed fat and soft tissue elements, and non-invasive relationship with the adjacent anatomy (Fig. 3). MRI of the mediastinal mass with chemical shift imaging showed the mass contained microscopic fat, with a signal intensity index of 67% consistent with benign thymic hyperplasia (Fig. 4) [1]. In summary, the imaging
findings of this mass were consistent with thymic hyperplasia, and the thymic hyperplasia decreased following treatment of his acromegaly.

**Discussion**

Here we present a case of thymic hyperplasia due to excess growth hormone stimulation in the setting of acromegaly. Thymic hyperplasia initially simulated a thymic tumor or lymphoma in the setting of the patient’s complex constellation of symptoms, however, the shape and texture of the thymus reinforced the diagnosis of thymic hyperplasia.

Acromegaly is an uncommon disorder of excess growth hormone production usually caused by a pituitary adenoma. Acromegaly has a prevalence of 60 cases per million [2]. Most cases of acromegaly are caused by benign somatotroph pituitary adenomas, and of those 70% are macroadenomas at the time of presentation [2]. Manifestations of acromegaly may be due multisystemic effects from growth hormone excess and associated endocrine abnormalities, or due to direct mass effect from the pituitary adenoma. While acral overgrowth and coarsened facial features are classic for acromegaly, they are often insidious onset and not the reason for presentation [3]. Presentation is more often due to the systemic complications like those in our patient who complained of neuropsychiatric effects, arthralgias, hyperhydrosis, and respiratory complications like upper airway obstruction [3].

The effect of GH excess on the thymus is of particular interest in our case. The thymus is a known target organ for GH [4]. Thymocytes and thymic epithelial cells express GH receptors. In vitro studies show that GH increases thymic epithelial cell proliferation and assists in stimulation of thymocyte proliferation. In vivo animal studies show that transgenic mice with overexpression of GH or GH-release hormone
demonstrate thymic overgrowth [4]. For these reasons, GH has been explored as a potential therapy to induce T-cell production in the setting of immunodeficiency. For example, in a small randomized prospective study of HIV-1 infected adults, administration of GH induced increased thymic mass and increased circulating CD4+ T-cells [5,6].

To our knowledge, this is only the second reported case of thymic hyperplasia in the setting of acromegaly [7]. Thymic hyperplasia has also been reported in a pediatric patient receiving GH replacement therapy [8]. Our patient displayed classic imaging features of thymic hyperplasia on CT and MRI. It is most likely that our patient’s thymic hyperplasia was due to GH excess given the evidence of the effect of GH on the thymus, and our patient’s decreasing thymic hyperplasia following treatment of his acromegaly.

**Conclusion**

Endogenous or exogenous growth hormone excess may cause thymic hyperplasia. Knowledge of this association may increase radiologists’ confidence in identifying thymic hyperplasia in this clinical setting in which a patient’s presentation may mimic systemic malignancy or infection, and help avoid unnecessary additional testing or biopsy.

**Patient Consent Statement**

The IRB at our institution does not require IRB approval of patient consent for case reports. No protected health information is shown in this case report.

**References**

[1] Priola AM, Priola SM, Ciccone G, Evangelista A, Cataldi A, Gned D, et al. Differentiation of rebound and lymphoid thymic hyperplasia from anterior mediastinal tumors with dual-echo chemical-shift MR imaging in adulthood: reliability of the chemical-shift ratio and signal intensity index. Radiology 2015;274(1):238–49 Epub 20140807 PubMed PMID: 25105246. doi:10.1148/radiol.14132665.

[2] Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol 2012;2012:540398 Epub 20120201 PubMed PMID: 22518126; PubMed Central PMCID: PMC3296170. doi:10.1155/2012/540398.

[3] Vilari L, Vilari CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary 2017;20(1):22–32 PubMed PMID: 27812777. doi:10.1007/s11102-016-0772-8.

[4] Savino W, Postel-Vinay MC, Smaniotto S, Dardenne M. The thymus gland: a target organ for growth hormone. Scand J Immunol 2002;55(5):442–52 Epub 2002/04/27 PubMed PMID: 11975755. doi:10.1046/j.1365-3083.2002.01077.x.

[5] Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, et al. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 2002;16(8):1103–11 PubMed PMID: 12004268. doi:10.1097/00002030-200205240-00003.

[6] Napolitano LA, Schmidt D, Gotway MB, Ameli N, Filbert EL, Ng MM, et al. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 2008;118(3):1085–98 PubMed PMID: 18292808; PubMed Central PMCID: PMC2248326. doi:10.1172/JCI32830.

[7] Bazzoni N, Ambrosi B, Arosio M, Barbareschi M, Losa M, Fagli G. Acromegaly and thymic hyperplasia: a case report. J Endocrinol Invest 1990;13(1):931–5 Epub 1990/12/01 PubMed PMID: 2090673. doi:10.1007/BF03349660.

[8] Polgreen L, Steiner M, Dietz CA, Manivel JC, Petryk A. Thymic hyperplasia in a child treated with growth hormone. Growth Horm IGF Res 2007;17(1):41–6 Epub 20061201 PubMed PMID: 17141546. doi:10.1016/j.yqghr.2006.10.005.